BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation

Group 2 innate lymphoid cells (ILC2) increase in frequency in eczema and allergic asthma patients, and thus represent a new therapeutic target cell for type-2 immune-mediated disease. The bromodomain and extra-terminal (BET) protein family of epigenetic regulators are known to support the expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerscher, Bernhard, Barlow, Jillian L., Rana, Batika M., Jolin, Helen E., Gogoi, Mayuri, Bartholomew, Michelle A., Jhamb, Deepali, Pandey, Ashutosh, Tough, David F., van Oosterhout, Antoon J. M., McKenzie, Andrew N. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465521/
https://www.ncbi.nlm.nih.gov/pubmed/31024538
http://dx.doi.org/10.3389/fimmu.2019.00678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465521/
https://www.ncbi.nlm.nih.gov/pubmed/31024538
http://dx.doi.org/10.3389/fimmu.2019.00678

Ejemplares similares